Andrea Jazel Rodríguez Herrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Jazel Rodríguez Herrera has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Todorovic Fabro
Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
2 shared publications Alexandre Todorovic Fabro
Ribeirao Preto Medical School, Ribeirao Preto, Brazil
1 shared publicationAndrea Antunes Cetlin
Ribeirao Preto Medical School, Ribeirao Preto, Brazil
1 shared publication- Barbara Barquette Silva da Rosa
Private Practice, São Paulo 04101-000, SP, Brazil
1 shared publication - Beatriz Domenici de Oliveira
Ilikia Brasil, São Paulo 01411-001, SP, Brazil
1 shared publication - Carlos Mario González-Zambrano
Sao Paulo State University
1 shared publication
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA879
Integrated predictive modeling for fibrotic progression in fibrosing interstitial lung diseases
Background: Fibrosing interstitial lung diseases (ILDs) represent a heterogeneous group of disorders characterized by progressive pulmonary fibrosis, functional decline, and increased mortality. Early identification of patients with a progressive phenotype remains a major clinical challenge, particularly because the true onset of disease prior to diagnosis is often unknown. In this setting, quantitative predictive modeling approaches have emerged as promising tools to provide insight into the natural history of fibrosing ILDs. Objective: To develop a temporal predictive model of disease progression based on clinical and functional variables (FVC, DLCO, age, sex, and time). Methods: Fifty patients who underwent lung biopsy between 2002 and 2019 were included after multidisciplinary discussion. Generalized Additive Mixed Models (GAMMs) were applied to describe FVC trajectories and retrospectively estimate disease duration. Model performance was evaluated through graphical diagnostics, cross-validation, and calculation of R², REML, MSE, and RMSE across all adjustment stages. Results: Time and clinical covariates (sex, age, DLCO) significantly influenced FVC progression. Model 1 and Model 2 represented the most parsimonious and the most comprehensive approaches, respectively, both showing consistent predictive performance after cross-validation. Conclusion: Additive mixed modeling allowed the estimation of disease duration and the precise description of functional progression in Fibrosing ILD underscoring its potential as a tool to support earlier diagnosis and prognostic classification (FAPESP 22/02821-0, 23/10186-6).
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA879
Integrated predictive modeling for fibrotic progression in fibrosing interstitial lung diseases
Background: Fibrosing interstitial lung diseases (ILDs) represent a heterogeneous group of disorders characterized by progressive pulmonary fibrosis, functional decline, and increased mortality. Early identification of patients with a progressive phenotype remains a major clinical challenge, particularly because the true onset of disease prior to diagnosis is often unknown. In this setting, quantitative predictive modeling approaches have emerged as promising tools to provide insight into the natural history of fibrosing ILDs. Objective: To develop a temporal predictive model of disease progression based on clinical and functional variables (FVC, DLCO, age, sex, and time). Methods: Fifty patients who underwent lung biopsy between 2002 and 2019 were included after multidisciplinary discussion. Generalized Additive Mixed Models (GAMMs) were applied to describe FVC trajectories and retrospectively estimate disease duration. Model performance was evaluated through graphical diagnostics, cross-validation, and calculation of R², REML, MSE, and RMSE across all adjustment stages. Results: Time and clinical covariates (sex, age, DLCO) significantly influenced FVC progression. Model 1 and Model 2 represented the most parsimonious and the most comprehensive approaches, respectively, both showing consistent predictive performance after cross-validation. Conclusion: Additive mixed modeling allowed the estimation of disease duration and the precise description of functional progression in Fibrosing ILD underscoring its potential as a tool to support earlier diagnosis and prognostic classification (FAPESP 22/02821-0, 23/10186-6).
- Open Access
Enhanced Neocollagenesis and Clinical Efficacy of a Novel Regenerative Diluent for Calcium Hydroxyapatite for Facial Rejuvenation: A 90-Day Clinical Trial
Facial aging is primarily characterized by the loss and disorganization of the dermal extracellular matrix (ECM), particularly collagen. Injectable biostimulators, such as calcium hydroxyapatite (CaHA), represent a vital non-surgical strategy to counteract these changes by inducing neocollagenesis. This 90-day clinical trial was designed to comparatively evaluate the efficacy of a novel regenerative solution (RS) diluent, formulated to potentially enhance the biostimulatory effects of standard CaHA (STIIM product), against a conventional diluent (control) for the treatment of facial laxity. Twenty-one subjects (N = 21) were randomized to receive CaHA diluted with either RS or control formulation. Efficacy was assessed using histological analysis (collagen I area percentage), ultrasound (US) for dermal density, and clinical laxity scoring. Histological analysis, although limited by a small subsample size (N = 3), showed qualitative and exploratory evidence of collagen remodeling in both groups. However, the RS group showed enhanced dermal thickening via US (15% increase vs. 5% control, p-value = 0.012), and improvement in clinical laxity. Furthermore, histological findings, including Picrosirius red staining, indicated that the RS group resulted in qualitatively greater ECM organization and more robust type I collagen fibers compared to the control. The novel regenerative solution is safe and demonstrates enhanced neocollagenesis and clinical efficacy over the conventional formulation, validating its potential as a diluent for CaHA for optimized facial rejuvenation.
Open AccessEnhanced Neocollagenesis and Clinical Efficacy of a Novel Regenerative Diluent for Calcium Hydroxyapatite for Facial Rejuvenation: A 90-Day Clinical Trial
Facial aging is primarily characterized by the loss and disorganization of the dermal extracellular matrix (ECM), particularly collagen. Injectable biostimulators, such as calcium hydroxyapatite (CaHA), represent a vital non-surgical strategy to counteract these changes by inducing neocollagenesis. This 90-day clinical trial was designed to comparatively evaluate the efficacy of a novel regenerative solution (RS) diluent, formulated to potentially enhance the biostimulatory effects of standard CaHA (STIIM product), against a conventional diluent (control) for the treatment of facial laxity. Twenty-one subjects (N = 21) were randomized to receive CaHA diluted with either RS or control formulation. Efficacy was assessed using histological analysis (collagen I area percentage), ultrasound (US) for dermal density, and clinical laxity scoring. Histological analysis, although limited by a small subsample size (N = 3), showed qualitative and exploratory evidence of collagen remodeling in both groups. However, the RS group showed enhanced dermal thickening via US (15% increase vs. 5% control, p-value = 0.012), and improvement in clinical laxity. Furthermore, histological findings, including Picrosirius red staining, indicated that the RS group resulted in qualitatively greater ECM organization and more robust type I collagen fibers compared to the control. The novel regenerative solution is safe and demonstrates enhanced neocollagenesis and clinical efficacy over the conventional formulation, validating its potential as a diluent for CaHA for optimized facial rejuvenation.
- Open Access
- 12 July 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (4) , 84
Pulmonary Hypertension Secondary to Fungal Infections: Underexplored Pathological Links
Background/Objective: Pulmonary fungal infections are a significant diagnostic challenge, primarily affecting immunocompromised individuals, such as those with HIV, cancer, or organ transplants, and they often lead to substantial morbidity and mortality if untreated. These infections trigger acute inflammatory and immune responses, which may progress to chronic inflammation. This process involves myofibroblast recruitment, the deposition of extracellular matrix, and vascular remodeling, ultimately contributing to pulmonary hypertension. Despite its clinical relevance, pulmonary hypertension secondary to fungal infections remains under-recognized in practice and poorly studied in research. Results/Conclusion: This narrative mini-review explores three key mechanisms underlying vascular remodeling in this context: (1) endothelial injury caused by fungal emboli or autoimmune reactions, (2) direct vascular remodeling during chronic infection driven by inflammation and fibrosis, and (3) distant vascular remodeling post-infection, as seen in granulomatous diseases like paracoccidioidomycosis. Further research and clinical screening for pulmonary hypertension in fungal infections are crucial to improving patient outcomes.
- 12 July 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (4) , 84
Open AccessPulmonary Hypertension Secondary to Fungal Infections: Underexplored Pathological Links
Background/Objective: Pulmonary fungal infections are a significant diagnostic challenge, primarily affecting immunocompromised individuals, such as those with HIV, cancer, or organ transplants, and they often lead to substantial morbidity and mortality if untreated. These infections trigger acute inflammatory and immune responses, which may progress to chronic inflammation. This process involves myofibroblast recruitment, the deposition of extracellular matrix, and vascular remodeling, ultimately contributing to pulmonary hypertension. Despite its clinical relevance, pulmonary hypertension secondary to fungal infections remains under-recognized in practice and poorly studied in research. Results/Conclusion: This narrative mini-review explores three key mechanisms underlying vascular remodeling in this context: (1) endothelial injury caused by fungal emboli or autoimmune reactions, (2) direct vascular remodeling during chronic infection driven by inflammation and fibrosis, and (3) distant vascular remodeling post-infection, as seen in granulomatous diseases like paracoccidioidomycosis. Further research and clinical screening for pulmonary hypertension in fungal infections are crucial to improving patient outcomes.